High COX-2 immunoreactivity in tumor spheroids and subcutaneous tumor allografts derived from mouse pheochromocytoma (MPC) cells demonstrates that available PPGL models are suitable for preclinical in vitro and in vivo testing of COX-2-targeting treatments. Here, PTGS2 is linked to pheochromocytoma.